Robin J Gunn
Overview
Explore the profile of Robin J Gunn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
528
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ketcham J, Harwood S, Aranda R, Aloiau A, Bobek B, Briere D, et al.
J Med Chem
. 2024 Mar;
67(6):4936-4949.
PMID: 38477582
The H1047R mutation of is highly prevalent in breast cancers and other solid tumors. Selectively targeting PI3Kα over PI3Kα is crucial due to the role that PI3Kα plays in normal...
2.
Smith C, Chen D, Christensen J, Coulombe R, Fethiere J, Gunn R, et al.
J Med Chem
. 2023 Dec;
67(1):774-781.
PMID: 38156904
SOS1 and SOS2 are guanine nucleotide exchange factors that mediate RTK-stimulated RAS activation. Selective SOS1:KRAS PPI inhibitors are currently under clinical investigation, whereas there are no reports to date of...
3.
Smith C, Kulyk S, Ahmad M, Arkhipova V, Christensen J, Gunn R, et al.
RSC Med Chem
. 2022 Dec;
13(12):1549-1564.
PMID: 36545438
Here we describe the early stages of a fragment-based lead discovery (FBLD) project for a recently elucidated synthetic lethal target, the PRMT5/MTA complex, for the treatment of -deleted cancers. Starting...
4.
Hallin J, Bowcut V, Calinisan A, Briere D, Hargis L, Engstrom L, et al.
Nat Med
. 2022 Oct;
28(10):2171-2182.
PMID: 36216931
Recent progress in targeting KRAS has provided both insight and inspiration for targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and anti-tumor efficacy of MRTX1133,...
5.
Smith C, Aranda R, Christensen J, Engstrom L, Gunn R, Ivetac A, et al.
Bioorg Med Chem
. 2022 Aug;
71:116947.
PMID: 35926325
MRTX1719 is an inhibitor of the PRMT5/MTA complex and recently entered clinical trials for the treatment of MTAP-deleted cancers. MRTX1719 is a class 3 atropisomeric compound that requires a chiral...
6.
Ketcham J, Haling J, Khare S, Bowcut V, Briere D, Burns A, et al.
J Med Chem
. 2022 Jul;
65(14):9678-9690.
PMID: 35833726
SOS1 is one of the major guanine nucleotide exchange factors that regulates the ability of KRAS to cycle through its "on" and "off" states. Disrupting the SOS1:KRAS protein-protein interaction (PPI)...
7.
Smith C, Aranda R, Bobinski T, Briere D, Burns A, Christensen J, et al.
J Med Chem
. 2022 Jan;
65(3):1749-1766.
PMID: 35041419
The PRMT5•MTA complex has recently emerged as a new synthetically lethal drug target for the treatment of -deleted cancers. Here, we report the discovery of development candidate . is a...
8.
Wang X, Allen S, Blake J, Bowcut V, Briere D, Calinisan A, et al.
J Med Chem
. 2021 Dec;
65(4):3123-3133.
PMID: 34889605
KRAS, the most common oncogenic KRAS mutation, is a promising target for the treatment of solid tumors. However, when compared to KRAS, selective inhibition of KRAS presents a significant challenge...
9.
Gunn R, Herrin B, Acharya S, Cooper M, Wilson I
J Mol Biol
. 2018 Mar;
430(9):1350-1367.
PMID: 29596914
Variable lymphocyte receptors (VLRs) are unconventional adaptive immune receptors relatively recently discovered in the phylogenetically ancient jawless vertebrates, lamprey and hagfish. VLRs bind antigens using a leucine-rich repeat fold and...
10.
Collins B, Gunn R, McKitrick T, Cummings R, Cooper M, Herrin B, et al.
Structure
. 2017 Oct;
25(11):1667-1678.e4.
PMID: 28988747
High-quality reagents to study and detect glycans with high specificity for research and clinical applications are severely lacking. Here, we structurally and functionally characterize several variable lymphocyte receptor (VLR)-based antibodies...